Telomir Pharmaceuticals, Inc. — Net Income by Fiscal Year
4 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/04a68d9e-4571-4867-a363-ebd86f3d12d4/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-10.4M | 2025-01-01 – 2025-12-31 | evidence 0001493152-26-010625 |
| FY 2024 | $-16.5M | 2024-01-01 – 2024-12-31 | evidence 0001493152-25-004872 |
| FY 2023 | $-13.1M | 2023-01-01 – 2023-12-31 | evidence 0001493152-24-012049 |
| FY 2022 | $-854.1k | 2022-01-01 – 2022-12-31 | evidence 0001493152-24-012049 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).